Ocular Therapeutix OCUL announces its next round of earnings this Friday, August 07. Here is Benzinga's look at Ocular Therapeutix's Q2 earnings report.
Earnings and Revenue
Sell-side analysts are expecting Ocular Therapeutix's loss per share to be near $0.31. In the same quarter last year, Ocular Therapeutix posted EPS of $-0.57. If the company were to post earnings in-line with the consensus estimate when it reports Friday, EPS would be up 45.61%. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
---|---|---|---|---|
EPS Estimate | -0.37 | -0.45 | -0.47 | -0.48 |
EPS Actual | -0.41 | -0.53 | -0.45 | -0.57 |
Revenue Estimate | 2.84 M | 2.54 M | 580.00 K | 740.00 K |
Revenue Actual | 2.61 M | 2.26 M | 829.00 K | 650.00 K |
Stock Performance
Over the last 52-week period, shares are up 93.1%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Ocular Therapeutix is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/ze3bnc2d
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.